Genetisch Modifizierte T-Zellen mit einem Modifizierten Intron im T-Zell-Rezeptor-Alpha-Gen
Anmelder: Precision Biosciences, Inc. 🇺🇸
Details
- Veröffentlichungs-Nr.
- EP4775669
- Anmeldetag
- 27. Juni 2018
- Veröffentlichung
- 15. Juli 2026
- Rechtsraum
- EP
- IPC
- C12N5/0783
Abstract
The present invention provides a genetically-modified T cell comprising in its genome a modified human T cell receptor alpha gene. The modified T cell receptor alpha gene comprises an exogenous sequence of interest inserted into an intron within the T cell receptor alpha gene that is positioned 5' upstream of TRAC exon 1. The exogenous sequence of interest can comprise an exogenous splice acceptor site and/or a poly A signal, which disrupts expression of the T cell receptor alpha subunit. The sequence of interest can also include a coding sequence for a polypeptide, such as a chimeric antigen receptor. Additionally, the endogenous splice donor site and the endogenous splice acceptor site flanking the intron are unmodified and/or remain functional. The invention further provides compositions and methods for producing the genetically-modified cell, and populations of the cell, and methods for the treatment of a disease, such as cancer, using such cells.
Anmelder
- Firma
- Precision Biosciences, Inc.
- Land
- 🇺🇸 USA
Die GRUND Intellectual Property Group in München ist auf Patent-, Marken- und Designrecht spezialisiert, mit Schwerpunkt Life Sciences (Biochemie, Neurowissenschaften, Immunologie) sowie Chemie und Pharmazie. Sie vertritt vor Ämtern wie WIPO, EPA, USPTO und DPMA und bietet Lizenzberatung sowie Due Diligence.